Intracranial efficacy of KRASG12C inhibitors adagrasib and sotorasib has been reported in patients with Br-M secondary to lung cancer.45,46 Adagrasib had an objective response rate of 42%, disease control rate of 90%, progression-free survival of 5.4 months, and median OS of 11.4 months in patients with non–small cell lung cancer.45 With more KRAS-targeted therapies entering clinical development in PDAC, we are looking forward to seeing their activity in patients with PDAC with Br-M. This evidence concerns the gene KRAS and lung carcinoma.